bluebird bio, Inc. (Nasdaq: BLUE) announces that management will present
at the Morgan Stanley Healthcare Conference to be held September 9 - 11,
2013 at the Grand Hyatt Hotel, New York, NY. Nick Leschly, Chief
bluebird, will provide an overview of the company at the Morgan Stanley
Conference on Wednesday, September 11, 2013 at 8:00 AM (ET).
To access a simultaneous webcast of Mr. Leschly's overview via the
internet, log on to the "Calendar of Events" section on the Investor and
Media page of the bluebird bio's website at http://investor.bluebirdbio.com.
Please connect to the website at least ten minutes prior to the start of
the presentation to ensure adequate time for a reliable connection and
any software download that may be necessary for the webcast.
A replay of the webcasts will be available on bluebird bio's website for
ninety days following the conference. The investor presentation will be
available for download in PDF format immediately following the
presentation in the "Calendar of Events" section of the Investor and
Media page of the bluebird bio's website at http://investor.bluebirdbio.com.
About bluebird bio, Inc.
bluebird bio is a clinical-stage
company committed to developing potentially transformative gene
therapies for severe genetic and orphan diseases. bluebird bio has two
clinical-stage programs in development. The most advanced product
candidate, Lenti-D, recently initiated a phase 2/3 study for the
treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare,
hereditary neurological disorder affecting young boys. The next most
advanced product candidate, LentiGlobin, is currently in a phase 1/2
study in France for the treatment of beta-thalassemia major and severe
sickle cell disease. A second phase 1/2 study with LentiGlobin has been
initiated in the United States for the treatment of beta-thalassemia
major.
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in partnership with Celgene
Corporation. bluebird bio has operations in Cambridge, Massachusetts,
San Francisco, California and Paris, France. For more information,
please visit www.bluebirdbio.com.
Forward-Looking Statements
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the advancement of our clinical trials. Any forward-looking
statements in this press release are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risk of cessation or delay of any of the ongoing or
planned clinical trials and/or our development of our product
candidates, the risk that the results of previously conducted studies
involving similar product candidates will not be repeated or observed in
ongoing or future studies involving current product candidates, the risk
that our collaboration with Celgene will not continue or will not be
successful, and the risk that any one or more of our product candidates
will not be successfully developed and commercialized. For a discussion
of other risks and uncertainties, and other important factors, any of
which could cause our actual results to differ from those contained in
the forward-looking statements, see the section entitled "Risk Factors"
in the final prospectus related to our initial public offering filed
with the Securities and Exchange Commission pursuant to Rule 424(b) of
the Securities Act, as well as discussions of potential risks,
uncertainties, and other important factors in our subsequent filings
with the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and bluebird bio
undertakes no duty to update this information unless required by law.
Copyright Business Wire 2013